Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• BRAF inhibitors are effective for advanced BRAF-mutant melanoma.
• Secondary cancers, including cutaneous squamous-cell carcinomas (SCCs) and melanomas, are known side effects.
• Emerging reports indicate additional secondary events like RAS-mutant leukemia and colorectal cancer recurrence.

Purpose of the Study:

• To review the clinical and mechanistic aspects of secondary cancers arising from BRAF inhibition.
• To discuss the role of paradoxical MAPK activation in these secondary tumors.
• To explore potential therapeutic strategies for managing BRAF-inhibitor-induced neoplasia.

Main Methods:

• Review of clinical data and mechanistic studies on BRAF inhibitor-induced secondary cancers.
• Analysis of the role of RAF isoform dimerization and MAPK pathway activation.
• Discussion of combination therapy with BRAF and MEK inhibitors.

Main Results:

• Paradoxical MAPK activation, driven by RAF isoform dimerization, is a key mechanism for secondary tumor development.
• While combined BRAF and MEK inhibition may prevent SCCs, its efficacy against all BRAF-inhibitor-driven pathologies remains uncertain.
• Pre-existing, partly transformed cells may contribute to secondary cancer development.

Conclusions:

• BRAF inhibition, despite its benefits, is associated with a spectrum of secondary malignancies.
• Understanding the mechanisms of paradoxical MAPK activation is crucial for managing these adverse events.
• Novel therapeutic strategies are needed to mitigate BRAF-inhibitor-induced neoplasia.